1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effects of Atrial Fibrillation on the Human Ventricle

      research-article
      1 , 1 , 2 , 1 , 2 , 1 , 3 , 3 , 4 , 1 , 1 , 2 , 5 , 6 , 2 , 7 , 8 , 5 , 9 , 10 , 5 , 7 , 4 , 2 , 1 , 3 , 2 , 11 , 1 , 2 ,
      Circulation Research
      Lippincott Williams & Wilkins
      atrial fibrillation, calcium-calmodulin-dependent protein kinase type 2, excitation contraction coupling, heart failure, oxidative stress

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Rationale:

          Atrial fibrillation (AF) and heart failure often coexist, but their interaction is poorly understood. Clinical data indicate that the arrhythmic component of AF may contribute to left ventricular (LV) dysfunction.

          Objective:

          This study investigates the effects and molecular mechanisms of AF on the human LV.

          Methods and Results:

          Ventricular myocardium from patients with aortic stenosis and preserved LV function with sinus rhythm or rate-controlled AF was studied. LV myocardium from patients with sinus rhythm and patients with AF showed no differences in fibrosis. In functional studies, systolic Ca 2+ transient amplitude of LV cardiomyocytes was reduced in patients with AF, while diastolic Ca 2+ levels and Ca 2+ transient kinetics were not statistically different. These results were confirmed in LV cardiomyocytes from nonfailing donors with sinus rhythm or AF. Moreover, normofrequent AF was simulated in vitro using arrhythmic or rhythmic pacing (both at 60 bpm). After 24 hours of AF-simulation, human LV cardiomyocytes from nonfailing donors showed an impaired Ca 2+ transient amplitude. For a standardized investigation of AF-simulation, human iPSC-cardiomyocytes were tested. Seven days of AF-simulation caused reduced systolic Ca 2+ transient amplitude and sarcoplasmic reticulum Ca 2+ load likely because of an increased diastolic sarcoplasmic reticulum Ca 2+ leak. Moreover, cytosolic Na + concentration was elevated and action potential duration was prolonged after AF-simulation. We detected an increased late Na + current as a potential trigger for the detrimentally altered Ca 2+/Na +-interplay. Mechanistically, reactive oxygen species were higher in the LV of patients with AF. CaMKII (Ca 2+/calmodulin-dependent protein kinase IIδc) was found to be more oxidized at Met281/282 in the LV of patients with AF leading to an increased CaMKII activity and consequent increased RyR2 phosphorylation. CaMKII inhibition and ROS scavenging ameliorated impaired systolic Ca 2+ handling after AF-simulation.

          Conclusions:

          AF causes distinct functional and molecular remodeling of the human LV. This translational study provides the first mechanistic characterization and the potential negative impact of AF in the absence of tachycardia on the human ventricle.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Early Rhythm-Control Therapy in Patients with Atrial Fibrillation

          Despite improvements in the management of atrial fibrillation, patients with this condition remain at increased risk for cardiovascular complications. It is unclear whether early rhythm-control therapy can reduce this risk.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Catheter Ablation for Atrial Fibrillation with Heart Failure

            Mortality and morbidity are higher among patients with atrial fibrillation and heart failure than among those with heart failure alone. Catheter ablation for atrial fibrillation has been proposed as a means of improving outcomes among patients with heart failure who are otherwise receiving appropriate treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study

              Atrial fibrillation (AF) causes substantial morbidity. It is uncertain whether AF is associated with excess mortality independent of associated cardiac conditions and risk factors. We examined the mortality of subjects 55 to 94 years of age who developed AF during 40 years of follow-up of the original Framingham Heart Study cohort. Of the original 5209 subjects, 296 men and 325 women (mean ages, 74 and 76 years, respectively) developed AF and met eligibility criteria. By pooled logistic regression, after adjustment for age, hypertension, smoking, diabetes, left ventricular hypertrophy, myocardial infarction, congestive heart failure, valvular heart disease, and stroke or transient ischemic attack, AF was associated with an OR for death of 1.5 (95% CI, 1.2 to 1.8) in men and 1.9 (95% CI, 1.5 to 2.2) in women. The risk of mortality conferred by AF did not significantly vary by age. However, there was a significant AF-sex interaction: AF diminished the female advantage in survival. In secondary multivariate analyses, in subjects free of valvular heart disease and preexisting cardiovascular disease, AF remained significantly associated with excess mortality, with about a doubling of mortality in both sexes. In subjects from the original cohort of the Framingham Heart Study, AF was associated with a 1.5- to 1.9-fold mortality risk after adjustment for the preexisting cardiovascular conditions with which AF was related. The decreased survival seen with AF was present in men and women and across a wide range of ages.
                Bookmark

                Author and article information

                Contributors
                Journal
                Circ Res
                Circ Res
                RES
                Circulation Research
                Lippincott Williams & Wilkins (Hagerstown, MD )
                0009-7330
                1524-4571
                23 February 2022
                01 April 2022
                23 February 2022
                : 130
                : 7
                : 994-1010
                Affiliations
                [1]Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany (S.P., M.K., T.S., M.P., T.K., A.P., L.S.M., S. Sossalla).
                [2]Clinic for Cardiology and Pneumology, Georg-August University Göttingen, and DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Germany (M.K., F.A., B.W., N.D., G.H., K.S.-B., S. Sossalla).
                [3]Institut für Forschung und Lehre (IFL), Department of Molecular and Experimental Cardiology and Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Germany (M.S., M.H., N.H.).
                [4]Institute of Pathology, University Hospital Regensburg, Germany (F.B., C.B.).
                [5]Department of Cardiology, Medical University of Graz, Austria (S.L.-H., S. Sedej, D.S.).
                [6]Institute of Experimental Cardiovascular Research, University Medical Centre Hamburg-Eppendorf, Germany (C.E.M.).
                [7]Department of Cardiothoracic Surgery, University Hospital Regensburg, Germany (D.C., C.S.).
                [8]Department of Internal Medicine I, University of Würzburg, Germany (T.H.F.).
                [9]Faculty of Medicine, University of Maribor, Maribor, Slovenia (S. Sedej).
                [10]BioTechMed Graz, Graz, Austria (S. Sedej).
                [11]Institute of Pharmacology and Toxicology, University of Würzburg, Germany (K.S.-B.).
                Author notes
                Correspondence to: Samuel Sossalla, MD‚ Universitätsklinikum Regensburg, Klinik für Innere Medizin II, Herzzentrum Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. Email samuel.sossalla@ 123456ukr.de
                Author information
                https://orcid.org/0000-0003-3245-5504
                https://orcid.org/0000-0002-6189-7259
                https://orcid.org/0000-0003-4971-6205
                https://orcid.org/0000-0002-2063-9368
                https://orcid.org/0000-0002-4419-6821
                https://orcid.org/0000-0002-5942-361X
                https://orcid.org/0000-0001-9915-4429
                https://orcid.org/0000-0002-3053-0008
                https://orcid.org/0000-0001-5137-7228
                https://orcid.org/0000-0001-8034-2673
                Article
                00006
                10.1161/CIRCRESAHA.121.319718
                8963444
                35193397
                a2016db1-28d5-4671-8e69-bc377701a29b
                © 2022 The Authors.

                Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                : 21 June 2021
                : 8 February 2022
                : 14 February 2022
                Categories
                10003
                10004
                10014
                10016
                10094
                Original Research
                Custom metadata
                TRUE
                T

                atrial fibrillation,calcium-calmodulin-dependent protein kinase type 2,excitation contraction coupling,heart failure,oxidative stress

                Comments

                Comment on this article